RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ryvu Therapeutics Stock

Ryvu Therapeutics Net Income 2024

Ryvu Therapeutics Net Income

-88.73 M PLN

Ticker

RVU.WA

ISIN

PLSELVT00013

WKN

A1JUH2

In 2024, Ryvu Therapeutics's profit amounted to -88.73 M PLN, a -3.67% increase from the -92.11 M PLN profit recorded in the previous year.

The Ryvu Therapeutics Net Income history

YEARNET INCOME (undefined PLN)
2026e-0.02
2025e-98.07
2024e-88.73
2023-92.11
2022-83.78
2021-79.08
2020-31.69
2019285.64
2018-0.11
20176.41
20162.72
20156.27
20145.85
2013-2.45
2012-5.55

Ryvu Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ryvu Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ryvu Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ryvu Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ryvu Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ryvu Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ryvu Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ryvu Therapeutics’s growth potential.

Ryvu Therapeutics Revenue, EBIT and net profit per share

DateRyvu Therapeutics RevenueRyvu Therapeutics EBITRyvu Therapeutics Net Income
2026e265.77 M PLN26.01 M PLN-22,754.26 PLN
2025e392.18 M PLN-72.87 M PLN-98.07 M PLN
2024e279.06 M PLN-92.72 M PLN-88.73 M PLN
202346.86 M PLN-97.38 M PLN-92.11 M PLN
202238.95 M PLN-70.69 M PLN-83.78 M PLN
202111.19 M PLN-78.89 M PLN-79.08 M PLN
202015.65 M PLN-35.67 M PLN-31.69 M PLN
20193.8 M PLN-45.39 M PLN285.64 M PLN
201877.21 M PLN-13.62 M PLN-106,320 PLN
201767.54 M PLN12.66 M PLN6.41 M PLN
201648.13 M PLN-1.22 M PLN2.72 M PLN
201541.03 M PLN2.07 M PLN6.27 M PLN
201428.86 M PLN5.27 M PLN5.85 M PLN
201313.05 M PLN-2.23 M PLN-2.45 M PLN
20129.51 M PLN-6.12 M PLN-5.55 M PLN

Ryvu Therapeutics stock margins

The Ryvu Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ryvu Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ryvu Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ryvu Therapeutics's sales revenue. A higher gross margin percentage indicates that the Ryvu Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ryvu Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ryvu Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ryvu Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ryvu Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ryvu Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ryvu Therapeutics Margin History

Ryvu Therapeutics Gross marginRyvu Therapeutics Profit marginRyvu Therapeutics EBIT marginRyvu Therapeutics Profit margin
2026e44.8 %9.79 %-0.01 %
2025e44.8 %-18.58 %-25.01 %
2024e44.8 %-33.23 %-31.8 %
202344.8 %-207.8 %-196.57 %
2022-1.65 %-181.5 %-215.12 %
2021-228.3 %-705.21 %-706.94 %
202044 %-227.92 %-202.47 %
2019-237.09 %-1,194.87 %7,520.15 %
201867.15 %-17.64 %-0.14 %
201761.61 %18.75 %9.49 %
201672.26 %-2.54 %5.65 %
201571.79 %5.05 %15.28 %
201451.06 %18.26 %20.27 %
201328.2 %-17.09 %-18.77 %
201212.93 %-64.35 %-58.36 %

Ryvu Therapeutics Aktienanalyse

What does Ryvu Therapeutics do?

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Ryvu Therapeutics's Profit Margins

The profit margins of Ryvu Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Ryvu Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Ryvu Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Ryvu Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Ryvu Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Ryvu Therapeutics stock

How much profit has Ryvu Therapeutics made this year?

Ryvu Therapeutics has made -88.73 M PLN this year.

How has the profit developed compared to last year?

The profit has increased by -3.67% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Ryvu Therapeutics publish its earnings?

Ryvu Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Ryvu Therapeutics?

The profits of Ryvu Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Ryvu Therapeutics?

You can learn more about the earnings of Ryvu Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Ryvu Therapeutics pay?

Over the past 12 months, Ryvu Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ryvu Therapeutics is expected to pay a dividend of 0 PLN.

What is the dividend yield of Ryvu Therapeutics?

The current dividend yield of Ryvu Therapeutics is .

When does Ryvu Therapeutics pay dividends?

Ryvu Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ryvu Therapeutics?

Ryvu Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ryvu Therapeutics?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ryvu Therapeutics located?

Ryvu Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ryvu Therapeutics from 9/13/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Ryvu Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Ryvu Therapeutics in the year 2023?

In the year 2023, Ryvu Therapeutics distributed 0 PLN as dividends.

In which currency does Ryvu Therapeutics pay out the dividend?

The dividends of Ryvu Therapeutics are distributed in PLN.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ryvu Therapeutics

Our stock analysis for Ryvu Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ryvu Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.